BioCryst's genetic disorder drug fails study, shares slump
0
(Reuters) - Drug developer BioCryst Pharmaceuticals Inc said its lead drug failed to reduce the frequency of recurrent swelling in patients with hereditary angioedema, a rare genetic condition.